Clinical features, Treatment and Prognosis Analysis of T-cell non-Hodgkin's Lymphoma

Objective: Regarding T-cell non-Hodgkin's lymphoma, it is important to explore both its clinical characteristics and treatment methods, as well as to make a good prognostic analysis. Methods: From 2017.02 to 2022.02, 40 patients with T-cell non-Hodgkin's lymphoma were seen in our hospital, and their data were implemented retrospectively. RESULTS: According to certain indicators of patients, they were divided into low-risk group (0-1 factors), low-medium-risk group (2 factors), high-medium-risk group (3 factors), and high-risk group (4-5 factors); after first-line treatment, the 3-year overall survival rates of patients with CR, PR, SD, and PD were 71%, 46%, 0%, and 0%, respectively; after treatment with CHOP-like regimens and other chemotherapy regimens, CR, PR, SD, and PD patients had 5-year overall survival rates of 44%, 36%, 0%, and 0%, respectively; after first-line treatment, CR patients were 16, PR patients were 16, and the effective rate was 80%, and SD+PD was 8. The CHOP-like regimen was used to treat 9 patients with CR, 9 patients with PR, 6 patients with SD, and 4 patients with PD; other chemotherapy regimens were used to treat 2 patients with CR, 4 patients with PR, 3 patients with SD, and 3 patients with PD, with an efficiency rate of 60% and an inefficiency rate of 40%. Conclusion: T-cell non-Hodgkin's lymphoma is easy to be misdiagnosed, and the prognosis analysis should be explored according to its clinical characteristics, combined with the treatment regimen, in order to ensure a significant treatment effect.